Cargando…

Progression of Liver Diseases

Detalles Bibliográficos
Autor principal:	Cuarterolo, Miriam Liliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2012
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412560/ https://www.ncbi.nlm.nih.gov/pubmed/22879833 http://dx.doi.org/10.5812/hepatmon.6626

Ejemplares similares

Development of immune‐related cell‐based machine learning for disease progression and prognosis of alcoholic liver disease
por: Zhang, Xu, et al.
Publicado: (2023)

NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues
por: Mushtaq, Kamran, et al.
Publicado: (2021)

Reply to “Follistatin-like protein 1 and chronic liver disease progression: a novel pro-inflammatory and pro-fibrogenic mediator?”
por: Rao, Jianhua, et al.
Publicado: (2022)

Celiac disease and liver
por: Collin, Pekka
Publicado: (2010)

Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues”
por: Ji, Dong, et al.
Publicado: (2021)

Disease progression in systemic sclerosis
por: van Leeuwen, Nina M, et al.
Publicado: (2021)

Liver fibrosis in patients with chronic liver diseases: are laboratory tests useful to diagnosis?
por: Leonardi, Salvatore, et al.
Publicado: (2011)

Liver histology and histochemistry in Wilson disease
por: Madakshira, Manoj Gopal, et al.
Publicado: (2018)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Comment on pediatric living donor liver transplantation decade progress in Shanghai: Characteristics and risks factors of mortality
por: Akbulut, Sami, et al.
Publicado: (2020)

Sex differences in progression of kidney disease in sickle cell disease
por: Ataga, Kenneth I., et al.
Publicado: (2022)

Gastroesophageal Reflux Disease Could Progress to Achalasia
por: Bognar, Laura, et al.
Publicado: (2017)

Eighteen-Year Disease Progression and Survival in CADASIL
por: Gravesteijn, Gido, et al.
Publicado: (2021)

Liver- Heart Inter- Relationship in Fatty Liver Disease Based on the Avicenna’s Point of View
por: KHADEM, Ebrahim, et al.
Publicado: (2013)

Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation
por: Bulinski, Catherine, et al.
Publicado: (2022)

Celiac Disease and Abnormal Liver Function Test
por: Nejad, Mohammad Rostami, et al.
Publicado: (2012)

Grover's Disease in a Liver Transplant Patient
por: Moon, Hye-Rim, et al.
Publicado: (2014)

Pathogenesis of Liver Injury in Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2020)

The Covid-19 Pandemic Constraints May Lead to Disease Progression for Patients with Liver Cancer Scheduled to Receive Locoregional Therapies: Single-Centre Retrospective Analysis in an Interventional Radiology Unit
por: Veiga, José, et al.
Publicado: (2021)

Colorectal cancer in pregnancy: a rapid progressive disease
por: Randawa, Abdullahi Jibril, et al.
Publicado: (2010)

Classical Hirayama Disease Presenting as Progressive Spastic Quadriparesis
por: Oommen, Abel Thomas, et al.
Publicado: (2023)

Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease?
por: Parsian, Hadi
Publicado: (2011)

Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease
por: Anania, Caterina, et al.
Publicado: (2011)

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease
por: Biquard, Louise, et al.
Publicado: (2020)

The Concept of Liver Disease Diagnosis in Avicenna’s Canon of Medicine
por: SHAHKARAMI, Efat, et al.
Publicado: (2013)

Importance of Variables in Nonalcoholic Fatty Liver Disease Patients
por: Garg, Vivek Kumar, et al.
Publicado: (2018)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

COVID-19 and liver disease: Are we missing something?
por: Gupta, Tarana
Publicado: (2022)

Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’
por: Ji, Dong, et al.
Publicado: (2020)

Neurodegeneration with Progressive Dystonia: Juvenile-Onset Tay–Sachs Disease
por: Kaur, Jasmine, et al.
Publicado: (2022)

“Hepatologia em Rede”: A Portuguese Association for the Study of the Liver (APEF) Initiative for the Improvement of Research in Liver Disease in Portugal
por: Oliveira, Rui Caetano, et al.
Publicado: (2023)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Is MELD score failing patients with liver disease and hepatorenal syndrome?
por: Sibulesky, Lena, et al.
Publicado: (2016)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion
por: Alsawat, Khalid, et al.
Publicado: (2020)

Concomitant inflammation/metabolism transcriptional regulatory networks in liver disease
por: Abbas, Tahany, et al.
Publicado: (2020)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Association of chronic liver disease with the prognosis of COVID-19 patients
por: Long, Junyu, et al.
Publicado: (2022)

Metabolic Phenotypes: Drivers of Health Outcomes in Fatty Liver Diseases
por: Charatcharoenwitthaya, Phunchai
Publicado: (2023)

Letter regarding “Evidence-based hyponatremia management in liver disease”
por: Theodorou, Daphne J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c9osasl7qn2al6t5vts11lavg9